BIM, PUMA, and the achilles' heel of oncogene addiction

Science Signaling

Volumn 6, Issue 268, 2013, Pages

  Roulston, Anne ^a   Muller, William J ^a   Shore, Gordon C ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BH3 PROTEIN; BIM PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; LAPATINIB; PROTEIN BCL 2; PUMA PROTEIN; TAMOXIFEN; TRASTUZUMAB; APOPTOSIS REGULATORY PROTEIN; BBC3 PROTEIN, HUMAN; BCL 2 LIKE PROTEIN 11; BCL-2-LIKE PROTEIN 11; ERBB2 PROTEIN, HUMAN; MEMBRANE PROTEIN; ONCOPROTEIN;

CANCER CELL CULTURE; CELL DEATH; DRUG POTENCY; GENE INACTIVATION; GENE INDUCTION; GENE MUTATION; ONCOGENE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; BIOLOGICAL MODEL; CELL PROLIFERATION; CELL SURVIVAL; DRUG DELIVERY SYSTEM; DRUG RESISTANCE; GENETICS; HUMAN; METHODOLOGY; NEOPLASM; PATHOPHYSIOLOGY;

APOPTOSIS REGULATORY PROTEINS; CELL PROLIFERATION; CELL SURVIVAL; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; HUMANS; MEMBRANE PROTEINS; MODELS, BIOLOGICAL; NEOPLASMS; ONCOGENES; PROTO-ONCOGENE PROTEINS; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION;

EID: 84875721996     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.2004113     Document Type: Review

References (39)

1. C. L. Sawyers, Shifting paradigms: The seeds of oncogene addiction. Nat. Med. 15, 1158-1161 (2009).
2. I. B. Weinstein, Cancer. Addiction to oncogenes - The Achilles heal of cancer. Science 297, 63-64 (2002).
3. I. B. Weinstein, A. Joe, D. Felsher, Oncogene addiction. Cancer Res. 68, 3077-3080, discussion 3080 (2008).
4. J. M. Goldman, J. V. Melo, Chronic myeloid leukemia - Advances in biology and new approaches to treatment. N. Engl. J. Med. 349, 1451-1464 (2003).
5. D. S. Askew, R. A. Ashmun, B. C. Simmons, J. L. Cleveland, Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene 6, 1915-1922 (1991).
6. G. I. Evan, A. H. Wyllie, C. S. Gilbert, T. D. Littlewood, H. Land, M. Brooks, C. M. Waters, L. Z. Penn, D. C. Hancock, Induction of apoptosis in fibroblasts by c-myc protein. Cell 69, 119-128 (1992).
7. G. R. Bean, Y. T. Ganesan, Y. Dong, S. Takeda, H. Liu, P. Chan, Y. Huang, L. A. Chodosh, G. P. Zambetti, J. J.-D. Hsieh, E. H.-Y. Cheng, PUMA and BIM are required for oncogene inactivationinduced apoptosis. Sci. Signal. 6, ra20 (2013).
8. K. W. Yip, J. C. Reed, Bcl-2 family proteins and cancer. Oncogene 27, 6398-6406 (2008).
9. A. G. Letai, Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nat. Rev. Cancer 8, 121-132 (2008).
10. R. J. Youle, A. Strasser, The BCL-2 protein family: Opposing activities that mediate cell death. Nat. Rev. Mol. Cell Biol. 9, 47-59 (2008).
11. L. Chen, S. N. Willis, A. Wei, B. J. Smith, J. I. Fletcher, M. G. Hinds, P. M. Colman, C. L. Day, J. M. Adams, D. C. Huang, Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol. Cell 17, 393-403 (2005).
12. N. N. Danial, S. J. Korsmeyer, Cell death: Critical control points. Cell 116, 205-219 (2004).
13. H. Kim, M. Rafiuddin-Shah, H. C. Tu, J. R. Jeffers, G. P. Zambetti, J. J. Hsieh, E. H. Cheng, Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat. Cell Biol. 8, 1348-1358 (2006).
14. L. Dunn, A. Demichele, Genomic predictors of outcome and treatment response in breast cancer. Mol. Diagn. Ther. 13, 73-90 (2009).
15. D. L. Nielsen, I. Kümler, J. A. Palshof, M. Andersson, Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. Breast 22, 1-12 (2013).
16. Q. B. She, S. Chandarlapaty, Q. Ye, J. Lobo, K. M. Haskell, K. R. Leander, D. DeFeo-Jones, H. E. Huber, N. Rosen, Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS ONE 3, e3065 (2008).
17. S. M. Brachmann, I. Hofmann, C. Schnell, C. Fritsch, S. Wee, H. Lane, S. Wang, C. Garcia- Echeverria, S. M. Maira, Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 106, 22299-22304 (2009).
18. D. B. Costa, B. Halmos, A. Kumar, S. T. Schumer, M. S. Huberman, T. J. Boggon, D. G. Tenen, S. Kobayashi, BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med. 4, 1669-1679, discussion 1680 (2007).
19. M. S. Cragg, J. Kuroda, H. Puthalakath, D. C. Huang, A. Strasser, Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PLoS Med. 4, 1681-1689, discussion 1690 (2007).
20. J. Deng, T. Shimamura, S. Perera, N. E. Carlson, D. Cai, G. I. Shapiro, K. K. Wong, A. Letai, Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion. Cancer Res. 67, 11867-11875 (2007).
21. A. C. Faber, D. Li, Y. Song, M. C. Liang, B. Y. Yeap, R. T. Bronson, E. Lifshits, Z. Chen, S. M. Maira, C. García-Echeverría, K. K. Wong, J. A. Engelman, Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc. Natl. Acad. Sci. U.S.A. 106, 19503-19508 (2009).
22. Y. Gong, R. Somwar, K. Politi, M. Balak, J. Chmielecki, X. Jiang, W. Pao, Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. PLoS Med. 4, e294 (2007).
23. S. Amente, J. Zhang, M. L. Lavadera, L. Lania, E. V. Avvedimento, B. Majello, Myc and PI3K/AKT signaling cooperatively repress FOXO3adependent PUMA and GADD45a gene expression. Nucleic Acids Res. 39, 9498-9507 (2011).
24. H. You, M. Pellegrini, K. Tsuchihara, K. Yamamoto, G. Hacker, M. Erlacher, A. Villunger, T. W. Mak, FOXO3a-dependent regulation of Puma in response to cytokine/growth factor withdrawal. J. Exp. Med. 203, 1657-1663 (2006).
25. D. Accili, K. C. Arden, FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell 117, 421-426 (2004).
26. E. L. Greer, A. Brunet, FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 24, 7410-7425 (2005).
27. S. E. Moody, C. J. Sarkisian, K. T. Hahn, E. J. Gunther, S. Pickup, K. D. Dugan, N. Innocent, R. D. Cardiff, M. D. Schnall, L. A. Chodosh, Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell 2, 451-461 (2002).
28. R. Ley, K. E. Ewings, K. Hadfield, S. J. Cook, Regulatory phosphorylation of Bim: Sorting out the ERK from the JNK. Cell Death Differ. 12, 1008-1014 (2005).
29. M. R. Quadros, S. Connelly, C. Kari, M. T. Abrams, E. Wickstrom, U. Rodeck, EGFR-dependent downregulation of Bim in epithelial cells requires MAPK and PKC-delta activities. Cancer Biol. Ther. 5, 498-504 (2006).
30. A. Sunters, S. Fernández de Mattos, M. Stahl, J. J. Brosens, G. Zoumpoulidou, C. A. Saunders, P. J. Coffer, R. H. Medema, R. C. Coombes, E. W. Lam, FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines. J. Biol. Chem. 278, 49795-49805 (2003).
31. X. Wang, W. R. Chen, D. Xing, A pathway from JNK through decreased ERK and Akt activities for FOXO3a nuclear translocation in response to UV irradiation. J. Cell. Physiol. 227, 1168-1178 (2012).
32. S. Guo, G. E. Sonenshein, Forkhead box transcription factor FOXO3a regulates estrogen receptor alpha expression and is repressed by the Her-2/neu/phosphatidylinositol 3-kinase/Akt signaling pathway. Mol. Cell. Biol. 24, 8681-8690 (2004).
33. S. Khatri, H. Yepiskoposyan, C. A. Gallo, P. Tandon, D. R. Plas, FOXO3a regulates glycolysis via transcriptional control of tumor suppressor TSC1. J. Biol. Chem. 285, 15960-15965 (2010).
34. O. R. Mikse, D. C. Blake Jr., N. R. Jones, Y. W. Sun, S. Amin, C. J. Gallagher, P. Lazarus, J. Weisz, C. R. Herzog, FOXO3 encodes a carcinogenactivated transcription factor frequently deleted in early-stage lung adenocarcinoma. Cancer Res. 70, 6205-6215 (2010).
35. A. Obrador-Hevia, M. Serra-Sitjar, J. Rodríguez, P. Villalonga, S. Fernández de Mattos, The tumour suppressor FOXO3 is a key regulator of mantle cell lymphoma proliferation and survival. Br. J. Haematol. 156, 334-345 (2012).
36. F. Ertel, M. Nguyen, A. Roulston, G. C. Shore, Programming cancer cells for high expression levels of Mcl1. EMBO Rep. 10.1038/embor.2013.20 (2013).
37. M. Campone, B. Noël, C. Couriaud, M. Grau, Y. Guillemin, F. Gautier, W. Gouraud, C. Charbonnel, L. Campion, P. Jézéquel, F. Braun, B. Barré, O. Coqueret, S. Barillé-Nion, P. Juin, c-Myc dependent expression of pro-apoptotic Bim renders HER2-overexpressing breast cancer cells dependent on anti-apoptotic Mcl-1. Mol. Cancer 10, 110 (2011).
38. A. P. Martin, C. Mitchell, M. Rahmani, K. P. Nephew, S. Grant, P. Dent, Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy. Cancer Biol. Ther. 8, 2084-2096 (2009).
39. K. K. Shiu, D. Wetterskog, A. Mackay, R. Natrajan, M. Lambros, D. Sims, I. Bajrami, R. Brough, J. Frankum, R. Sharpe, C. Marchio, H. Horlings, F. Reyal, M. van der Vijver, N. Turner, J. S. Reis- Filho, C. J. Lord, A. Ashworth, Integrative molecular and functional profiling of ERBB2-amplified breast cancers identifies new genetic dependencies. Oncogene 10.1038/onc.2012.625 (2013).